# US 2025/0152597 A1 · Linezolid formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152597 A1
- Document ID: US20250152597A1
- Status: Published application
- Kind: A1
- Application number: 19/025,236
- Filed: 2025-01-16
- Published: 2025-05-15
- Earliest claimed: 2017-11-16
- Assignees: Persica Pharmaceuticals Ltd.
- Applicants: Persica Pharmaceuticals Ltd.
- Inventors: Lloyd Czaplewski; Sarah Guest
- Web page: https://patentgrep.com/patent/US20250152597A1

## CPC

- A61K 31/5355: Non-condensed oxazines and containing further heterocyclic rings
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61K 47/18: Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61K 49/0438: {Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol}
- A61K 49/0457: {Semi-solid forms, ointments, gels, hydrogels}
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 31/04: Antibacterial agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to injectable, thermosensitive hydrogel compositions comprising linezolid for relieving and/or treating chronic low back pain (CLBP).

## Claims

### Claim 1

An injectable pharmaceutical formulation comprising:
(a) an effective amount of linezolid,
(b) a thermosensitive hydrogel comprising poloxamer and iohexol, and optionally
(c) at least one pharmaceutically acceptable excipient,
wherein linezolid forms a suspension in the thermosensitive hydrogel.

### Claim 2 (depends on 1)

The injectable pharmaceutical formulation of claim 1, wherein linezolid is linezolid Form II.

### Claim 3 (depends on 2)

The injectable pharmaceutical formulation of claim 2, wherein the poloxamer is poloxamer 407 and wherein said poloxamer 407 is present from about 9.5% to about 17% by weight of the formulation.

### Claim 4 (depends on 3)

The injectable pharmaceutical formulation of claim 3, wherein said poloxamer 407 is present from about 10.8% to about 12.8% by weight of the formulation.

### Claim 5 (depends on 1, 2, 3, 4)

The injectable pharmaceutical formulation of any of claims 1-4, wherein iohexol is present from about 14% to about 59% by weight of the formulation.

### Claim 6 (depends on 5)

The injectable pharmaceutical formulation of claim 5, wherein iohexol is present from about 17% to about 30% by weight of the formulation.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The injectable pharmaceutical formulation of any of claims 1-6, wherein the suspension gels at a temperature from about 26° C. to about 38° C.

### Claim 8 (depends on 7)

The injectable pharmaceutical formulation of claim 7, wherein the suspension gels at a temperature from about 32° C. to about 36° C.

### Claim 9 (depends on 7)

The injectable pharmaceutical formulation of claim 7, wherein the suspension gels at a temperature from about 26° C. to about 32° C.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The injectable pharmaceutical formulation of any of claims 1-9, wherein the concentration of linezolid is about 1% to about 20% by weight of the formulation.

### Claim 11

An injectable pharmaceutical formulation comprising about 2.5 to 20% linezolid form II, about 17% to 30% iohexol, and about 10.8% to 12.8% poloxamer by weight of the formulation.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The injectable pharmaceutical formulation of any of claims 1-11, wherein the injectable pharmaceutical formulation is prepared for administering to an intervertebral disc, intervertebral space, intra-articular space, site adjacent to bone edema, ligament, bone, joint, tendon, or tendon and bone junction.

### Claim 13 (depends on 12)

The injectable pharmaceutical composition of claim 12, wherein the bone, joint, ligament or tendon is a bone, joint, ligament, or tendon associated with the spine.

### Claim 14 (depends on 13)

The injectable pharmaceutical composition of claim 13, wherein the bone, joint, ligament, or tendon associated with the spine is associated with a cervical, thoracic, lumbar or sacral vertebra.

### Claim 15

An injectable linezolid formulation comprising:
(a) a linezolid Form II powder,
(b) a thermosensitive hydrogel comprising poloxamer 407 and iohexol, and optionally
(c) at least one excipient,
wherein said linezolid formulation is prepared through the method comprising:
(i) milling linezolid form II to a defined powder,
(ii) preparing a unit of linezolid powder from step (i) and sterilizing the preparation,
(iii) preparing and sterilizing the thermosensitive hydrogel comprising poloxamer 407 and iohexol, and
(iv) suspending said linezolid powder from step (ii) in the thermosensitive hydrogel from step (iii).

### Claim 16 (depends on 15)

The injectable linezolid formulation of claim 15, wherein the linezolid powder is sterilized by gamma irradiation.

### Claim 17 (depends on 16)

The injectable linezolid formulation of claim 16, wherein the steps (iii) and (iv) are performed at a lower temperature than the steps (i) and (ii).

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The injectable pharmaceutical composition of any of claims 1-17, for use in medicine.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The injectable pharmaceutical composition of any of claims 1-17, for use in a method of treating or preventing lower back pain in a subject comprising administration of the injectable pharmaceutical composition.

### Claim 20 (depends on 19)

The injectable pharmaceutical composition for use of claim 19, wherein the pain is acute pain, sub-acute pain, chronic pain, local pain, radicular pain, referred pain, lumbar or cervical pain.

### Claim 21 (depends on 20)

The injectable pharmaceutical composition for use of claim 20, wherein the pain is lumbar or cervical pain that is associated with Modic changes or bone edema.

### Claim 22 (depends on 21)

The injectable pharmaceutical composition for use of claim 21, wherein the subject is suspected of, or has, a bacterial infection.

### Claim 23 (depends on 20)

The injectable pharmaceutical composition for use of claim 20 wherein the injectable pharmaceutical composition is injected into an intervertebral disc, intervertebral space, intra-articular space, ligament, tendon, tendon and bone junction, or site adjacent to bone edema.

### Claim 24 (depends on 23)

The injectable pharmaceutical composition for use of claim 23, wherein the injectable pharmaceutical composition is injected adjacent to or into a site of Modic change or bone edema.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The injectable pharmaceutical composition of any of claims 1-17, for use in a method of simultaneously relieving or ameliorating pain in a subject and eliminating bacterial infection in a cervical, thoracic, lumbar or sacral vertebra of said subject comprising the administration of the injectable pharmaceutical composition by injection to an area in, near or around the infected vertebrae.

### Claim 26

A kit comprising:
(a) a linezolid Form II powder, and
(b) a thermosensitive hydrogel comprising poloxamer 407 and iohexol.

### Claim 27 (depends on 26)

The kit of claim 26 further comprising a syringe and a needle for injection.

### Claim 28

A thermosensitive hydrogel for drug delivery comprising:
(a) poloxamer 407 which is present in the hydrogel at a concentration of about 10% to about 17% by weight of the hydrogel; and
(b) Iohexol which is present in the hydrogel at a concentration of about 14.5% to about 62.5% by weight of the hydrogel,
wherein the hydrogel forms gel at a temperature between 26° C. and 36° C.
